Market research
CPH1.F Histogen Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 289K
- P/E ratio
- Not available
- Analyst target
- 2.7
- Dividend yield
- 0.0%
- Beta
- -0.17
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 289K
- P/E ratio
- Not available
- Analyst target
- 2.7
- Dividend yield
- 0.0%
- Beta
- -0.17
About
About Histogen Inc
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CPH1.F discussion.
5 years, 5 months ago
Histogen Inc is currently in a long term downtrend where the price is trading 24.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.6.
Histogen Inc's total revenue sank by 69.4% to $478K since the same quarter in the previous year.
Its net income has dropped by 51.9% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 141.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Histogen Inc gets an overall score of 1/5.